RNA — Atrium Therapeutics, Inc.

RNA closed at $8.05 (-1.83%) on Oct 26, 2026. Float: 145.9M shares. Latest SEC filing: 8-K on Oct 27, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for RNA in the TickerWise workspace.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 511
• Website: http://www.atriumtherapeutics.com

Latest SEC filings for RNA

• 2026-10-278-K
• 2026-08-14SCHEDULE 13G
• 2026-04-27SCHEDULE 13G
• 2026-04-17S-8
• 2026-04-08SCHEDULE 13G
• 2026-02-27S-8 POS
• 2026-02-27S-8 POS
• 2026-02-27S-8 POS
• 2026-02-27S-8 POS
• 2026-02-27S-8 POS

Latest RNA news

• 2026-10-10Atrium Therapeutics (NASDAQ: RNA) lines up $50 million private placement Read article
• 2026-10-08Atrium Therapeutics raises $50M in private placement Read article
• 2026-10-08Atrium Therapeutics Announces $50 Million Private Placement Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.